Mayne flags FY earnings jump despite weak quarter performance
MELBOURNE: ASX-listed pharma takeover target Mayne expects full year underlying earnings to range from $47m
MELBOURNE: ASX-listed pharma takeover target Mayne expects full year underlying earnings to range from $47m